ARXX Therapeutics ApS

CVR 40868151 · Private limited company (ApS) · Active · Low risk

ARXX Therapeutics ApS is a Private limited company (ApS), founded on , based in Herlev. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 0.1% over the next 12 months, which is 0.1 times the average for Danish companies. 6 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 1.7m and a net result of DKK 707k. CEO: Jonas Hallén, Berte Aagot Hedding Poulsson.

Bankruptcy risk for ARXX Therapeutics ApS

0.1%
probability of bankruptcy within 12 months
Low risk

0.1 × the average (1.41%) · higher risk than 38% of active Danish companies

Lowest riskHighest risk

Increases the risk

Reporting classReporting class B, mikrovirksomhed · bankruptcy rate 23.5%2.7×
Time since new CEO1 yrs · bankruptcy rate 16.2%1.8×
Auditor's statementNo assurance · bankruptcy rate 13.2%1.5×
Number of auditors (historical)0 · bankruptcy rate 12.5%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×
CEO's other companies0 · bankruptcy rate 10.9%1.2×
Audit opted outYes · bankruptcy rate 10.4%1.2×

Reduces the risk

Current ratio500%+ · bankruptcy rate 1.5%0.17×
Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Equity ratio60%+ · bankruptcy rate 3.3%0.38×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Gross profit growth10%–30% · bankruptcy rate 4.5%0.51×
Return on assets15%+ · bankruptcy rate 5.1%0.58×
Negative equityNo · bankruptcy rate 5.1%0.58×
Loss for the yearNo · bankruptcy rate 5.3%0.60×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
40868151
Status
Active
Company type
Private limited company (ApS)
Founded
(7 years)
Address
c/o ECIT Services A/S, Hørkær 12A
2730 Herlev
Municipality
Herlev
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 100k
Audit opted out
Yes

Warning signs

Annual reports filed late1 of 6
Missing annual reportNo
Negative equityNo
Equity ratio87.6%
Current ratio2,601%
Moves (last 2 years)0
CEO changes in total3
CEO's previous bankruptcies0
Other companies at the address62
Going-concern uncertaintyNo

Financials and key figures

Financial year202520242023
RevenueDKK 3.7mDKK 2.6mDKK 2.8m
Gross profitDKK 2.8mDKK 2.3mDKK 1.9m
Net profitDKK 707kDKK 117kDKK 270k
EquityDKK 1.7mDKK 982kDKK 865k
Total assetsDKK 1.9mDKK 1.4mDKK 1.2m
CashDKK 537kDKK 348k–
Short-term debtDKK 74kDKK 359k–

Latest annual report: Reporting class B, mikrovirksomhed · auditor's statement: No assurance.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025103
1 Jan 2024 – 31 Dec 2024175
1 Jan 2023 – 31 Dec 2023176
1 Jan 2022 – 31 Dec 2022178
1 Jan 2021 – 31 Dec 2021181
1 Oct 2019 – 31 Dec 2020187 Late

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOJonas HallénCurrent
CEOBerte Aagot Hedding PoulssonCurrent
CEOSusanne Stuffers
BoardFarzad Abdi-Dezfuli
BoardJonas Hallén
BoardSusanne Stuffers
Owner (100%)ARXX THERAPEUTICS ASCurrent
FounderARXX THERAPEUTICS ASCurrent

Address history (2 moves)

c/o ECIT Services A/S, Hørkær 12A, 2730 Herlev
c/o ECIT Services A/S, Hørkær 12A, 2730 Herlev
c/o ECIT Services A/S, Hassellunden 16, 2765 Smørum

Other companies at the same address

Similar companies in Herlev

Questions and answers about ARXX Therapeutics ApS

Has ARXX Therapeutics ApS gone bankrupt?

No, ARXX Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of ARXX Therapeutics ApS?

Our model estimates a bankruptcy risk of 0.1% over the next 12 months (low risk), which is 0.1 times the average for Danish companies.

Who is the CEO of ARXX Therapeutics ApS?

Jonas Hallén, Berte Aagot Hedding Poulsson are the CEOs of ARXX Therapeutics ApS.

When was ARXX Therapeutics ApS founded?

ARXX Therapeutics ApS was founded on 1 October 2019.

What is the equity of ARXX Therapeutics ApS?

Equity was DKK 1.7m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.